A significant setback has occurred for Moderna, as the Food and Drug Administration has refused to review its latest experimental flu vaccine. The decision halts the process before it even begins, raising questions about the standards for new vaccine development.
The core of the issue lies with the trial’s design, specifically the benchmark used for comparison. Dr. Vinay Prasad, the FDA’s chief vaccine official, declined to authorize the review, citing concerns that Moderna compared its new vaccine against Fluarix Quadrivalent – a less effective, existing flu shot.
Prasad, director of the Center for Biologics Evaluation and Research, argued the trial wasn’t “adequate and well-controlled.” He emphasized that using a less-than-optimal existing vaccine as a comparison doesn’t represent the current “best-available standard of care” for influenza prevention.
Moderna’s CEO, Stéphane Bancel, publicly expressed his disappointment, stating the FDA had not identified any safety or efficacy concerns with the vaccine itself. He further asserted the decision hinders America’s progress in innovative medicine development.
Bancel defended the trial’s methodology, pointing out the study design and control group were discussed and agreed upon with the FDA’s CBER prior to commencement. He emphasized the importance of continued access to American-made innovations for vulnerable populations.
The company’s president, Dr. Stephen Hoge, conveyed confusion to the New York Times, describing the FDA’s refusal as “surprising” and expressing a need to understand the reasoning behind the sudden shift. The situation remains unclear from Moderna’s perspective.
This decision signals a potential change in the FDA’s approach, particularly under the leadership of Robert F. Kennedy Jr., a long-time critic of vaccine practices. It suggests a move towards stricter scrutiny of pharmaceutical companies, especially in light of past concerns surrounding COVID-19 vaccines.
The refusal has sparked debate, with some questioning whether demanding more rigorous trials from the industry could ultimately bolster public trust in vaccines. The conversation centers on balancing innovation with the need for robust scientific validation.
Experts are highlighting the unusual nature of the situation, noting the FDA previously approved the control vaccine used in the Moderna trial. This raises questions about whether the agency is now retroactively applying higher standards or if other factors are at play.
